Company intelligence / Profile preview
Palobiofarma
Barcelona, Catalonia, Spainpalobiofarma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Palobiofarma has reported positive top-line results from a Phase 2 trial of its oral small molecule PBF‑680 for moderate-to-severe COPD. The company’s pipeline includes additional programs targeting cancer, autoimmune diseases, and sleep disorders through selective modulation of adenosine receptors. Several compounds are advancing through preclinical and clinical development with partnerships supporting further characterization and candidate nomination.
- Therapeutic areas
- OncologyPulmonologyNeurologyImmunology
- Modalities
- Small molecules (selective adenosine receptor modulators)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with CROs, research centers & universities for pharmacology/toxicology studies; no major pharma partnership publicly disclosed yet.
Beyond the preview
Go deeper on Palobiofarma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Palobiofarma.